California Pharmacist vol. 72, no. 3 FALL 2025 - Flipbook - Page 24
Weekly SC semaglutide
2.4 mg
STEP-HFpEF (2023)16
Weekly SC albiglutide
30 mg
Albiglutide E昀昀ects
on Cardiac Function,
Cardiac Metabolism,
and Exercise Capacity
in CHF (2016)19
Change in KCCQ-CSS:
+7.8 (CI: 4.8–10.9)
Change in body weight:
–10.7% (CI: –11.9 to –9.4)
Change in 6-minute walk distance:
+20.3 m (CI: 8.6- 32.1)
Change in LVEF:
2.4% vs. 4.4% (P = 0.22)
Change in 6-minute walk distance:
18 vs 9 (P = 0.58)
Change in peak oxygen consumption:
0.9 vs –0.6 (P = 0.02)
529
82
¥¥¥° ±
° ± ¥ ¨¥
¥ ¥ ¢
Dulaglutide
Heart Failure
« ¦« ¦ ¦¦¥P¯ ª
©« ª¦« ª ¦¥
P¯
«
≥ «
¥¦« ¦¥P¯ ©
ª
ª«
ª©¦« ©ª
ª
£
¢≥
°
± ° ± ¥
ª
ǻ
Liraglutide
¢
«
©ª
¢ ª
£
©
22
vol. 72, no.3 | California Pharmacist
©
° ± ª¦
¦«
¢
ª
¢
¢
¨
¢ ® ¦
¢
¢
¢ ¦
Emerging Indications
